STORM’s METTL3 Inhibitor Effective Against AML

Plans Global Clinical RNA Epigenetic Drug Program in early 2022

 
• By Sten Stovall
  
Emerging Company Profile Regular column feature image Version 2
STORM is targeting RNA modifying enzymes for development of new anti-cancer drugs • Source: Informa
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Emerging Company Profiles

More from Start-Ups & SMEs